PharmaNutrition最新文献

{"title":"Characterization of the modulatory effect of zeaxanthin isolated from maize kernels on cellular signaling pathways associated with hyperglycemia-induced HepG2 cell proliferation","authors":"T. Maradagi ,&nbsp;N.M. Stephen ,&nbsp;R. Kumar ,&nbsp;K.N. Ramudu ,&nbsp;G. Ponesakki","doi":"10.1016/j.phanu.2024.100376","DOIUrl":"https://doi.org/10.1016/j.phanu.2024.100376","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Carotenoids are the group of antioxidant </span>phytonutrients<span><span>, found to repress carcinogenesis by modulating multiple cellular signaling pathways. Since diabetes patients have two to three folds increased risk of liver cancer, the present study aimed to explore the role of </span>zeaxanthin on various molecular targets of high glucose-mediated human </span></span>hepatocellular carcinoma<span> (HepG2) cell proliferation.</span></p></div><div><h3>Methods</h3><p><span><span>The antiproliferative effect<span> of zeaxanthin was examined by WST-1 assay. The DCFH-DA fluorescence dye was used to measure the intracellular </span></span>ROS<span> levels. The modulatory effect of zeaxanthin on the protein expression<span> of MAPK-p38, Akt, and ERK, and antioxidant markers such as Nrf2, SOD2, HO1, and catalase, and </span></span></span>apoptosis<span><span> markers, Bcl2, P53, and cleaved caspase 3 was measured by </span>western blotting. Apoptosis-inducing effect of zeaxanthin in high glucose subjected HepG2 cells was examined using DAPI staining.</span></p></div><div><h3>Results</h3><p>Zeaxanthin exhibits an effective growth inhibition in high glucose subjected HepG2 cells. It drastically repressed high glucose-mediated elevation of ROS levels. Further, zeaxanthin suppressed hyperglycemia-mediated ROS-driven p38 activation to mitigate HepG2 cell proliferation. Zeaxanthin also switched on the apoptosis pathway in hyperglycemic HepG2 cells. The apoptosis induction by zeaxanthin was confirmed with downregulated Bcl2 and P53 and upregulated cleaved caspase 3 protein expression.</p></div><div><h3>Conclusions</h3><p>The current findings substantiate the previous findings that zeaxanthin has greater potential than lutein in sensitizing hyperglycemic HepG2 cells by modulating multiple signaling pathways. The study highlights the importance of zeaxanthin as a powerful phytonutrient which possesses chemotherapeutic potential against diabetes-associated liver cancer progression.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139549011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and sociodemographic factors associated with overweight in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A cross-sectional study","authors":"Joana Dias da Costa ,&nbsp;Giuseppe Mario Carmine Pastura ,&nbsp;Cleber Nascimento do Carmo ,&nbsp;Renata Ribeiro Spinelli ,&nbsp;Pamela Melo Krok Fedeszen ,&nbsp;Letícia Victoria Souza da Cunha ,&nbsp;Beatriz Bastos de Araújo ,&nbsp;Patricia de Carvalho Padilha","doi":"10.1016/j.phanu.2024.100375","DOIUrl":"10.1016/j.phanu.2024.100375","url":null,"abstract":"<div><h3>Background</h3><p>Overweight has been increasing globally in various age groups, including children and adolescents. Despite efforts to reduce instances of childhood obesity, research has shown that children and adolescents with attention deficit hyperactivity disorder (ADHD) tend to be overweight more often than the general population. In this context, the aim of this study is to evaluate the clinical and sociodemographic factors associated with overweight in children and adolescents with ADHD treated at a university hospital in Rio de Janeiro.</p></div><div><h3>Methods</h3><p>This cross-sectional study included 40 children and adolescents aged 6–18 years who were diagnosed with ADHD. Height/age and body mass index (BMI)/age indices were used for anthropometric assessment, and the percentages of fat mass (%FM) and fat-free mass (%FFM) were estimated using bioelectrical impedance. Clinical (lipid profile and comorbidities) and sociodemographic variables were also obtained. The association between clinical and sociodemographic variables and overweight status was investigated using multiple correspondence analysis (MCA). The significance level was set at p &lt; 0.05.</p></div><div><h3>Results</h3><p>Excessive weight occurred in 42.5% (n = 17) of the participants, 67% (n = 20) had inadequat% FM, and 27.5% (n = 11) had dyslipidemia. According to the MCA, “greater number of people in the family”, “lower maternal education”, “presence of comorbidities, and “generalized anxiety disorder” were more frequent among those with excess weight.</p></div><div><h3>Conclusion</h3><p>The findings provide insights on the clinical and sociodemographic variables associated with being overweight in children and adolescents with ADHD, which may contribute to the early detection of possible inadequacies in anthropometric status.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of n-3 polyunsaturated fatty acids on inflammation status in cancer patients: Updated systematic review and dose- and time-response meta-analysis","authors":"Mehrdad Jamali ,&nbsp;Meysam Zarezadeh ,&nbsp;Parsa Jamilian ,&nbsp;Zohreh Ghoreishi","doi":"10.1016/j.phanu.2023.100372","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100372","url":null,"abstract":"<div><h3>Background</h3><p>Reducing inflammation levels can potentially reduce treatment-induced complications in cancer patients. This meta-analysis aimed to determine the effect of n-3 PUFAs on three main biomarkers of inflammation: tumor necrosis factor-α(TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6).</p></div><div><h3>Methods</h3><p>A systematic search was conducted on PubMed, Scopus, and the Web of Science databases to find relevant studies. The difference between the intervention and control arms results was assessed by standardized mean differences (SMD) along with a 95% confidence interval.</p></div><div><h3>Result</h3><p>The study found that the SMD for TNF-α, CRP, and IL-6 was −0.63(95%CI:−0.89,−0.37, P &lt; 0.001), −0.27(95%CI:−0.64,0.10, P = 0.15), −0.59(95%CI:−0.89,−0.29, P &lt; 0.001) respectively, comparing the effects of n-3 PUFAs on study subjects compared to control. Subgroup analyses revealed heterogeneity sources for TNF-α and IL-6 but not for CRP. The study did not detect any indication of publication bias in the cases of TNF-α and CRP but detected it for IL-6.</p></div><div><h3>Conclusion</h3><p>N-3 PUFAs caused a significant reduction in levels of TNF-α IL-6 but not CRP in cancer patients. The findings support that n-3 PUFAs could be used as an add-on treatment for cancer patients, possibly because they reduce inflammation and do not have any known side effects in moderate doses.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139108718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of L-carnitine supplementation on lipid profiles in adults: A systematic review and dose-response meta-analysis","authors":"Sina Raissi Dehkordi ,&nbsp;Mahsa Malekahmadi ,&nbsp;Mahlagha Nikbaf-Shandiz ,&nbsp;Niloufar Rasaei ,&nbsp;Amir Mehdi Hosseini ,&nbsp;Hossein Bahari ,&nbsp;Samira Rastgoo ,&nbsp;Omid Asbaghi ,&nbsp;Farideh Shiraseb ,&nbsp;Reza Behmadi","doi":"10.1016/j.phanu.2023.100374","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100374","url":null,"abstract":"<div><h3>Background</h3><p><span><span>We aimed to conduct this meta-analysis to systematically assess the effects of L-carnitine supplementation on levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), </span>total cholesterol (TC), </span>Apolipoprotein A<span> (Apo A) and Apolipoprotein B (Apo B) in adults.</span></p></div><div><h3>Methods</h3><p><span><span>A systematic search was done in databases such as PubMed, ISI Web of Science, the Cochrane Library, and </span>Scopus to find acceptable articles up to April 2023. </span>Randomized controlled trials (RCTs) evaluating the effects of L-carnitine on lipid profiles in adults were included considering the specified inclusion and exclusion criteria.</p></div><div><h3>Results</h3><p><span>We included the 60 RCTs (n = 3933) with 64 effect sizes in this study. L-carnitine supplementation had a significant effect on TG (WMD= −10.33 mg/dl, P &lt; 0.001), TC (WMD= −6.91 mg/dl, P = 0.032), LDL-C (WMD= −7.51 mg/dl, P &lt; 0.001), HDL-C (WMD= 1.80 mg/dl, P = 0.007) in intervention, compared to a placebo group, in the pooled analysis. Moreover, we conducted the subgroup analyses that have shown L-carnitine supplementation had a reduction effect on TG in baseline ≥ 150 mg/dl, and in any trial duration (&lt;12 and ≥12 weeks), intervention dose ≥ 2 g/day, in overweight (25–29.9 kg/m</span>²) and obese (&gt;30 kg/m²), in type ² diabetes and other health status. Also, L-carnitine significantly impacted TC in baseline ≥ 200 mg/dl, trial duration ≥ 12 weeks, intervention dose ≥ 2 g/day, obese (&gt;30 kg/m²), and other health statuses.</p></div><div><h3>Conclusions</h3><p>Our results indicate L-carnitine significantly reduces the serum levels of TC, LDL-C, and TG and increases HDL-C, but it had no significant effect on the levels of apolipoproteins.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139100607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short communication: Nutrient intake and total caloric intake are not entirely proportionate to metabolic disease prevalence","authors":"Cato Wiegers,&nbsp;Olaf F.A. Larsen","doi":"10.1016/j.phanu.2023.100373","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100373","url":null,"abstract":"<div><h3>Background</h3><p>Dietary composition has been brought up as one of the main causes of the dramatic rise of metabolic disease over the past years. Intake of specific (macro)nutrients such as fat and sugar have been associated with higher risk of metabolic syndrome, as well as a general excessive energy intake. In a previous study, we investigated trends in (macro)nutrient intake and metabolic disease in the United States, but total caloric intake was not addressed.</p></div><div><h3>Methods</h3><p>In this follow-up study, data on total caloric intake per capita per day was collected for the United States from 1900 until now. Total caloric intake was also calculated based on previously collected data on nutrient intake per capita per day. Trends were visualized and statistically compared with data previously collected regarding metabolic syndrome, obesity, and diabetes.</p></div><div><h3>Results</h3><p>It was found that total caloric intake has risen considerably, from approximately 3200 in the year 1900 to nearly 4000 from the year 2000 until now. The caloric intake did not correlate with the trends in metabolic disease prevalence, except for diagnosed (pre)diabetes.</p></div><div><h3>Conclusions</h3><p>As highlighted in our previous work, there is a discrepancy between nutrient and caloric intake and the steep rise in metabolic disease. This suggests that there are other factors that need to be addressed in future studies, in addition to excess nutrient and energy intake, as suspected causes of the metabolic disease epidemic.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213434423000452/pdfft?md5=0ecc4792ae3eb8dc20dc320537f613e6&pid=1-s2.0-S2213434423000452-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139033934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zeaxanthin exerts anti-inflammatory effects in vitro and provides significant neuroprotection in mice subjected to transient middle cerebral artery occlusion","authors":"Daniele La Russa ,&nbsp;Giorgia Manni ,&nbsp;Chiara Di Santo ,&nbsp;Benedetta Pieroni ,&nbsp;Daniela Pellegrino ,&nbsp;Francisco J. Barba ,&nbsp;Giacinto Bagetta ,&nbsp;Francesca Fallarino ,&nbsp;Domenico Montesano ,&nbsp;Diana Amantea","doi":"10.1016/j.phanu.2023.100368","DOIUrl":"10.1016/j.phanu.2023.100368","url":null,"abstract":"<div><h3>Background and aims</h3><p>Preclinical and clinical evidence supports the value of nutraceuticals as prophylactic or adjuvant therapeutics to reduce stroke risk or to improve post-stroke recovery. Given the beneficial properties of xantophyll carotenoids, we aimed at assessing the putative neuroprotective effects of zeaxanthin, evaluating its anti-inflammatory and anti-oxidant properties in vitro and in vivo.</p></div><div><h3>Methods and results</h3><p>Exposure to zeaxanthin (25 μM for 24 h) reverted the elevation of inducible nitric oxide synthase (iNOS) expression prompted by tumor necrosis factor (TNF)-α in macrophages from mouse bone marrow. In mice subjected to transient (30-min) middle cerebral artery occlusion (MCAo), oral pre-treatment with zeaxanthin (2 mg/kg, 48 h, 24 h and 1 h before MCAo) prevented the elevation of serum levels of reactive oxygen species induced by the ischemic insult, while it did not affect the reduction of antioxidant barrier efficiency. Analysis of lipid peroxidation showed a significant increase in hydroperoxide level in the brain of mice subjected to MCAo, and the latter effect was inhibited by pretreatment with zeaxanthin. Finally, we originally demonstrated that oral administration of zeaxanthin significantly reduced neurological deficits and brain damage caused by transient MCAo in mice.</p></div><div><h3>Conclusions</h3><p>Our data, in combination with the evidence that zeaxanthin is a well-tolerated carotenoid, strengthen the nutritional value of this xanthophyll in the prevention of ischemic stroke injury.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213434423000403/pdfft?md5=d6f2c7200f49dc6eb6edf2946d3e7e7b&pid=1-s2.0-S2213434423000403-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139013976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of flaxseed as an effective approach for improving lipid profile parameters: An updated systematic review and meta-analysis of randomized controlled trials","authors":"Amir Hossein Moridpour ,&nbsp;Masomeh Goodarzi ,&nbsp;Zeynab Kavyani ,&nbsp;Negarsadat Nademi ,&nbsp;Maziar Daneshvar ,&nbsp;Vali Musazadeh ,&nbsp;Amir Hossein Faghfouri","doi":"10.1016/j.phanu.2023.100366","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100366","url":null,"abstract":"<div><h3>Background</h3><p>Numerous studies have shown the beneficial effects of flaxseed on lipid profile parameters; however, some others have reported contradictory results.</p></div><div><h3>Aim of the review</h3><p>The current study, therefore, aimed to provide a thorough understanding of the effects of flaxseed on lipid profile parameters in adults.</p></div><div><h3>Methods</h3><p>To this end, a comprehensive systematic search was conducted to collect the required trials from PubMed, Scopus<span><span>, Embase, </span>Cochrane Library, Web of Science databases, and Google Scholar up to December 2022.</span></p></div><div><h3>Results</h3><p>75 trials were included in our meta-analysis (two trials were only presented as a systematic review). Our study results indicated that the flaxseed supplementation significantly decreased the total levels of cholesterol (TC) (SMD: −0.57; 95% CI: −0.80, −0.33, <em>P</em><span> &lt; 0.001), triglyceride (TG) (SMD: −0.61; 95% CI: −0.87, −0.35, </span><em>P</em> &lt; 0.001), low-density lipoprotein-cholesterol (LDL-C) (SMD: −0.36; 95% CI: −0.61, −0.11; <em>P</em> = 0.005), and LDL-C/HDL-C ratios (SMD: −0.92, 95% CI: −1.35, −0.49, <em>P</em> &lt; 0.010). However, flaxseed did not change the levels of high-density lipoprotein-cholesterol (HDL-C) (SMD: 0.16; 95% CI: −0.03, 0.35, <em>P</em> = 0.097), and TC/HDL-C ratio (SMD: −0.35; 95% CI: −0.81, 0.11; <em>P</em> = 0.139).</p></div><div><h3>Conclusion</h3><p>It was concluded that the flaxseed supplementation may have improved the lipid profile. Therefore, it was recommended that flaxseed should be used as an adjuvant anti-hyperlipidemic agent.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138769689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of supplementation with a multi-species synbiotic on serum lipid profile, abundance of beneficial gut bacteria and firmicutes to bacteroidetes ratio in patients with dyslipidemia; a randomized, double-blind, placebo-controlled, clinical trial","authors":"Shekoufeh Salamat ,&nbsp;Mohammad Reza Tabandeh ,&nbsp;Alireza Jahan-Mihan ,&nbsp;Anahita Mansoori","doi":"10.1016/j.phanu.2023.100367","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100367","url":null,"abstract":"<div><h3>Background</h3><p><span><span><span><span>Dysbiosis an imbalance of </span>gut microbiota (GM) may contribute to the development of </span>metabolic disorders<span> including dyslipidemia<span>. Synbiotics have been suggested to modulate GM composition and in turn, they may alter </span></span></span>lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on </span>serum lipid<span><span> profile, abundance of dominant gut bacteria, and also the Firmicutes to </span>Bacteroidetes (F/B) ratio in adults with dyslipidemia.</span></p></div><div><h3>Methods</h3><p><span>Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×10</span>¹⁰<span><span><span><span> colony forming units<span>, CFU/gram) six species of probiotic<span> microorganisms with 5-gram inulin and </span></span></span>fructooligosaccharide (FOS) in equal amounts as </span>prebiotics. Serum lipid profile, </span>fecal bacteria<span><span> abundance, dietary intake, physical activity level (PAL), and </span>anthropometric measures, were assessed at the baseline and after intervention.</span></span></p></div><div><h3>Results</h3><p>No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal <span><em>Firmicutes, Bacteroidetes, </em><em>Lactobacillus</em></span>, and <span><em>Bifidobacterium</em></span> was significantly increased in the synbiotic group (p &lt; 0.0001, p &lt; 0.0001, p &lt; 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.</p></div><div><h3>Conclusions</h3><p>Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138656947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous vitamin C against acute respiratory distress syndrome: A narrative review","authors":"Alberto Boretti","doi":"10.1016/j.phanu.2023.100365","DOIUrl":"10.1016/j.phanu.2023.100365","url":null,"abstract":"<div><h3>Background</h3><p><span>The use of intravenous vitamin C<span> (IV-Vit-C) in the context of acute respiratory distress syndrome (ARDS) has been a topic of interest and research. ARDS is a severe and life-threatening form of respiratory failure that can be triggered by various factors, including infections, trauma, and inflammatory conditions. Some studies and </span></span>clinical trials<span> have explored the potential benefits of high-dose intravenous vitamin C in the treatment<span> of ARDS, particularly in the context of severe respiratory illnesses such as those caused by viral infections.</span></span></p></div><div><h3>Methods</h3><p>Two literature reviews are performed by using the google scholar data base (scholar.google.com), one searching for “CITRIS-ALI”, and the other searching for “COVID-19 Vitamin C”, without any time restrictions, and selecting specific works, and citing or cited works, deemed appropriate. All the works included in the c19early.org data base are then indirectly considered through their statistical summary of improvements.</p></div><div><h3>Results</h3><p>Most of the studies support the use of IV-Vit-C against ARDS in general, including the COVID-19 induced ARDS. From the statistical analysis of 66 COVID-19 Vit-C studies, both IV and oral, there is a 18 % improvement in prophylaxis (RR 0.82 CI 0.69–0.97), a 37 % improvement in early treatment (RR 0.63, CI 0.41–0.98), and 21 % improvement in late treatment (RR 0.79, CI 0.70–0.88). Specific to this latter result are 39 studies of the 66.</p></div><div><h3>Conclusions</h3><p>While IV-Vit-C was not a cure for COVID-19, it was a pragmatic but effectual means to reduce the COVID-19 mortality in cases of late infections and ARDS. IV and oral Vit-C may be considered one of the tools treating general ARDS.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138624041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis","authors":"Zeynab Kavyani ,&nbsp;Erfan shahhosseini ,&nbsp;Amir Hossein Moridpour ,&nbsp;Maryam Falahatzadeh ,&nbsp;Mahdi Vajdi ,&nbsp;Vali Musazadeh ,&nbsp;Gholamreza Askari","doi":"10.1016/j.phanu.2023.100364","DOIUrl":"https://doi.org/10.1016/j.phanu.2023.100364","url":null,"abstract":"<div><h3>Background</h3><p>Several meta-analyses reported berberine supplementation improves lipid profile and obesity indices, but findings remain conflicting.</p></div><div><h3>Aim of the review</h3><p>Therefore, we carried out an umbrella review of meta-analysis in order to examine whether berberine supplementation on lipid profile and obesity indices.</p></div><div><h3>Methods</h3><p>A systematic search was conducted on PubMed, Scopus<span>, Embase, Web of Science, and Google Scholar up to December 2022.</span></p></div><div><h3>Results</h3><p>Berberine supplementation was effective in reducing low-density lipoprotein cholesterol (LDL-C) (ES_SMD<span>: −0.56 mg/dL; 95% CI: −0.74 to −0.38, p &lt; 0.001), total cholesterol (TC) (ES</span>_SMD<span>: −0.57 mg/dL, 95% CI: −0.69 to −0.44, p &lt; 0.001), triglyceride (TG) (ES</span>_SMD: −0.47 mg/dL; 95% CI: −0.56 to −0.37, p &lt; 0.001) according to SMD analysis. In addition, berberine significantly increased high-density lipoprotein cholesterol (HDL-C) (ES_SMD: 0.14 mg/dL; 95% CI: 0.08–0.20, p &lt; 0.001) according to SMD analysis. Also, the findings showed that berberine resulted in a significant decrease in waist circumference (WC) (ES _WMD: −1.30 cm; 95% CI: −1.91 to −0.69, p &lt; 0.001), but not in body weight (ES_WMD<span>: −0.86 kg; 95% CI: −2.12 to 0.41), body mass index (BMI) (ES</span>_WMD: −0.57 kg/m²; 95% CI: −1.21 to 0.06, p = 0.078, and ES_SMD: −0.28 kg/m²; 95% CI: −070 to 0.14, p = 0.186), and waist-to-height ratio (WHR) levels (ES_SMD: −0.40; 95% CI: −1.26 to 0.47, p = 0.369).</p></div><div><h3>Conclusion</h3><p>The results of our study revealed that the supplementation of berberine could be effective in improving WC, and lipid profile, although the impact of this supplement on obesity indices needs further investigation.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138448097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}